SCHEMBL20140377

SCHEMBL20140377

FC(F)(F)CCn1nc(-c2nc(C(F)(F)F)n[nH]2)c2cccnc21

nearest known ligand 0.41

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
PDE5A O76074 7/20 0.41
GUCY1A1 Q02108 12/20 0.36
GUCY1B1 Q02153 12/20 0.36
GSK3B P49841 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20140169 0.91 GUCY1A1 (0.41) PDE5AGUCY1A1GUCY1B1
SCHEMBL21787437 0.86 PDE5A (0.43) PDE5AGUCY1A1GUCY1B1GSK3B
SCHEMBL20139738 0.85 GUCY1A1 (0.35) PDE5AGUCY1A1GUCY1B1
SCHEMBL20161154 0.84 L3MBTL1 (0.50) PDE5A
SCHEMBL20140339 0.83 L3MBTL1 (0.40) PDE5A
SCHEMBL20140449 0.83 PDE5A (0.40) PDE5A
SCHEMBL20161254 0.83 PDE5A (0.40) PDE5A
SCHEMBL20140418 0.83 L3MBTL1 (0.38) PDE5AGUCY1A1GUCY1B1
SCHEMBL20161279 0.82 L3MBTL1 (0.37) PDE5A
SCHEMBL20148908 0.82 PDE5A (0.51) PDE5A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12435080-B2 sGC stimulators TISENTO THERAPEUTICS INC. (US) 2025-10-07 US disclosed
US-20220017515-A1 sGC STIMULATORS TISENTO THERAPEUTICS INC. 2022-01-20 US disclosed
US-20220017515-A1 sGC STIMULATORS TISENTO THERAPEUTICS INC. 2022-01-20 US disclosed
US-11180493-B2 SGC stimulators CYCLERION THERAPEUTICS, INC. (US) 2021-11-23 US disclosed
US-11180493-B2 SGC stimulators CYCLERION THERAPEUTICS, INC. (US) 2021-11-23 US disclosed
US-20200071318-A1 SGC STIMULATORS TISENTO THERAPEUTICS INC. 2020-03-05 US disclosed
US-20200071318-A1 SGC STIMULATORS TISENTO THERAPEUTICS INC. 2020-03-05 US disclosed
EP-3538520-A2 SGC STIMULATORS Cyclerion Therapeutics, Inc. (US) 2019-09-18 EP disclosed
WO-2018111795-A2 USE OF SGC STIMULATORS FOR THE TREATMENT OF ESOPHAGEAL MOTILITY DISORDERS IRONWOOD PHARMACEUTICALS, INC. (US) 2018-06-21 WO disclosed
WO-2018089330-A2 SGC STIMULATORS IRONWOOD PHARMACEUTICALS, INC. (US) 2018-05-17 WO disclosed
WO-2018089330-A2 SGC STIMULATORS IRONWOOD PHARMACEUTICALS, INC. (US) 2018-05-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200071318-A1 SGC STIMULATORS GUCY1A2, GMPS, PDE2A PDE5A 12/4885GUCY1A1 4/4885GUCY1B1 6/4885
US-20220017515-A1 sGC STIMULATORS GUCY1A2, PRKG1, PDE2A PDE5A 12/4885GUCY1A1 4/4885GUCY1B1 6/4885
US-12435080-B2 sGC stimulators GUCY1A2, PRKG1, PDE2A PDE5A 12/4885GUCY1A1 4/4885GUCY1B1 6/4885
US-11180493-B2 SGC stimulators GUCY1A2, GMPS, PDE2A PDE5A 12/4885GUCY1A1 4/4885GUCY1B1 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.